The Business Research Company’s Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth And Change
LONDON, GREATER LONDON, UK, September 21, 2021 /EINPresswire.com/ — According to the new market research report ‘Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth And Change’ published by The Business Research Company, the alpha mannosidosis market size is expected to grow from $7.50 million in 2020 to $8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis, use of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment and advancements in treatment drugs. The alpha mannosidosis market is expected to reach $17.91 million in 2025 at a CAGR of 19.1%. The increasing investments on research are expected to contribute to the growth of the alpha mannosidosis market in the forecast period.
Request For A Sample For The Global Alpha Mannosidosis Market Report:
The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis (organizations, sole traders and partnerships) that provides treatment for alpha mannosidosis, which is a lysosomal storage disorder. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Alpha-mannosidosis is a rare genetic inherited condition that affects the organs and tissues of the person suffering from the disease. The treatment therapy focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules.
Trends In The Global Alpha Mannosidosis Market
The advancements in treatment for alpha mannosidosis like pharmacological therapy are gaining traction in the alpha mannosidosis market. For instance, in 2018 – Chiesi Group, an international research-focused Healthcare company, announced that it has received a positive opinion recommending the marketing authorization of Velmanase Alfa, under the brand name Lamzede from the European Medicines Agency Committee for Medicinal Products for Human Use. Lamzede is an enzyme replacement therapy intended to provide or supplement natural alpha-mannosidase, an enzyme that helps with the degradation of mannose–rich oligosaccharides and thus prevents their accumulation in various tissues in the body.
Global Alpha Mannosidosis Market Segments:
The global alpha mannosidosis market is further segmented based on therapy type, indication, end-user and geography.
By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy
By Indication: Type I, Type II, Type III
By End-User: Hospitals, Specialty Clinics
By Geography: The global alpha mannosidosis market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, the North American alpha mannosidosis market accounts for the largest share in the global alpha mannosidosis market.
Read More On The Report For The Global Alpha Mannosidosis Market At:
Alpha Mannosidosis Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides alpha mannosidosis global market overviews, analyzes and forecasts market size and growth for the global alpha mannosidosis global market, alpha mannosidosis global market share, alpha mannosidosis global market players, alpha mannosidosis global market segments and geographies, alpha mannosidosis global market’s leading competitors’ revenues, profiles and market shares. The alpha mannosidosis global market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Read Alpha Mannosidosis Global Market Report 2021 from The Business Research Company for information on the following:
Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries
Alpha Mannosidosis Market Organizations Covered: Chiesi Farmaceutici S.p.A.., Nuo Therapeutics, and Zymenex.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Get a quick glimpse of our services here:
Here is a list of reports from The Business Research Company similar to the Alpha Mannosidosis Global Market Report 2021:
Hematology Diagnostic Devices And Equipment Global Market Report 2021 – By Product (Instruments, Consumables), By End User (Hospitals, Specialized Diagnostic Centers, Specialized Research Institutes), By Instruments (Analyzers, Flow Cytometers), By Consumables (Reagents, Stains), By Application (Drug Testing, Auto Immune Disease, Cancer, Diabetes Mellitus, Infectious Disease), COVID-19 Impact And Recovery
Cell And Gene Therapy Market – By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Neurological Disorders, Others) And By Region, Opportunities And Strategies – Global Forecast To 2030
Gene Therapy Global Market Report 2021 – By Gene Type (Antigen, Cytokine, Suicide Gene), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases), By End Users (Hospitals, Homecare, Specialty Clinics), COVID-19 Growth And Change
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Source: EIN Presswire